Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analyst consensus is “Hold”: Of nine brokerages, five rate Xencor a buy, three hold, and one sell; the average 12-month price target is $24.86.
• Xencor shares rose 4.6% to $27.26, trading near the upper end of their 52-week range of $7.83 to $30.61 and above both their 50-day and 200-day moving averages.
• Quarterly results exceeded expectations: Xencor reported an adjusted loss of $0.29 per share versus the $0.80 consensus loss, while revenue reached $51.22 million—up 17.4% year over year and well above the $18.89 million estimate.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received an average recommendation of "Hold" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $24.8571.

A number of research firms have weighed in on XNCR. JPMorgan Chase & Co. raised their price target on Xencor from $13.00 to $14.00 and gave the company a "neutral" rating in a research note on Monday, May 11th. Zacks Research raised Xencor from a "strong sell" rating to a "hold" rating in a research report on Monday, July 6th. Truist Financial decreased their target price on Xencor from $29.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Xencor in a report on Wednesday, June 24th. Finally, Wedbush increased their price target on shares of Xencor from $26.00 to $30.00 and gave the company an "outperform" rating in a research note on Thursday, August 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of XNCR. ProShare Advisors LLC lifted its position in Xencor by 6.5% in the fourth quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company's stock valued at $258,000 after acquiring an additional 1,026 shares during the last quarter. Cerity Partners LLC boosted its stake in Xencor by 3.8% in the fourth quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company's stock valued at $479,000 after acquiring an additional 1,143 shares in the last quarter. State of Tennessee Department of Treasury grew its holdings in shares of Xencor by 6.2% during the second quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company's stock worth $241,000 after purchasing an additional 1,784 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Xencor by 3.3% during the second quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company's stock worth $550,000 after purchasing an additional 2,256 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 3,018 shares in the last quarter.

Xencor Trading Up 4.6%

Shares of NASDAQ:XNCR opened at $27.26 on Tuesday. Xencor has a 52 week low of $7.83 and a 52 week high of $30.61. The company's 50 day moving average is $20.07 and its two-hundred day moving average is $14.90. The company has a market cap of $2.03 billion, a PE ratio of -12.56 and a beta of 0.85.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.51. The business had revenue of $51.22 million during the quarter, compared to analysts' expectations of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company's revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.41) EPS. As a group, equities research analysts expect that Xencor will post -3 EPS for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source